Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

New Mole Rat Cancer Resistance Pathway Discovered

By BiotechDaily International staff writers
Posted on 12 Nov 2012
Print article
Image: A blind mole rat shown on the background of dying necrotic blind mole rat tissue culture cells (Photo courtesy of University of Rochester).
Image: A blind mole rat shown on the background of dying necrotic blind mole rat tissue culture cells (Photo courtesy of University of Rochester).
In a study of a species of mole rats, biologists have identified a cancer resistance mechanism different from another long-lived, cancer-resistant mole rat species discovered earlier.

The researchers, led by Professor Vera Gorbunova and Assistant Professor Andrei Seluanov of the University of Rochester (Rochester, NY, USA), found that abnormally growing cells from blind mole rats secrete interferon-beta (IFN-β) that triggers those and neighboring cells to rapidly die. Blind mole rats (BMR) from the Middle East and naked mole rats from Africa, both subterranean rodents with long life spans, are the only examined mammals never known to naturally develop cancer and in which spontaneous tumors have never been observed. Previously, a team led by Profs. Seluanov and Gorbunova identified an anticancer mechanism in the naked mole rat in which the p16 gene causes cancerous cells from these rats to become hypersensitive to overcrowding, preventing them from proliferating further. "We expected blind mole rats to have a similar mechanism [...]. Instead, we discovered they've evolved their own mechanism," said Prof. Seluanov.

In the current study, growth of BMR fibroblast cells in vitro, from the BMR species Spalax judaei and Spalax golani, were examined. The cells were made to actively proliferate for an abnormally large number of population doublings, after which the precancerous-like cells began secreting IFN-β and the cultures underwent massive, concerted necrotic cell death within 3 days. The necrotic cell death phenomenon was independent of culture conditions or telomere shortening. Sequestration of p53 and Rb proteins using SV40 large T antigen completely rescued necrotic cell death. The results suggest that cancer resistance in BMR is conferred by massive necrotic response to overproliferation mediated by p53 and Rb pathways, and triggered by the release of IFN-β.

"Not only were the cancerous cells killed off, but so were the adjacent cells, which may also be prone to tumorous behavior," said Prof. Seluanov. "While people don't use the same cancer-killing mechanism as blind mole rats, we may be able to combat some cancers and prolong life if we could stimulate the same clean sweep reaction in cancerous human cells," said Prof. Gorbunova. Profs. Gorbunova and Seluanov added that next they want to determine what initiates this suicidal secretion of IFN-β.

The study was published online ahead of print November 5, 2012, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:
University of Rochester


Print article

Channels

Genomics/Proteomics

view channel
Image: Follicular helper T-cells (TFH cells, shown in blue) play a crucial role in the maturation of antibody-producing B-cells (shown in green). Activated B-cells give rise germinal centers (shown in red), where mature B-cells proliferate and produce highly specific antibodies against pathogens. Top left: normal germinal center in a mouse tonsil. All others: Germinal centers fail to form when the interaction between ICOS and TBK1 is interrupted (Photo courtesy of Dr. Kok-Fai Kong, La Jolla Institute for Allergy and Immunology).

Molecular Pathway Controlling High-affinity Antibody Production Identified

A molecular pathway has been identified that controls formation of follicular helper T-cells (TFH cells) germinal centers and production of high-affinity antibodies through interaction with the inducible... Read more

Drug Discovery

view channel

Experimental Small-Molecule Anticancer Drug Blocks RAS-binding Domains

The experimental small-molecule anticancer drug rigosertib was shown to block tumor growth by acting as an RAS-mimetic and interacting with the RAS binding domains of RAF kinases, resulting in their inability to bind to RAS, which inhibited the RAS-RAF-MEK pathway. Oncogenic activation of RAS genes due to point mutations... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.